Document:

Exhibit
10.10

 

AMENDMENT
TO ADVISORY BOARD AGREEMENT

 

This
Amendment to Advisory Board Agreement (this “Amendment”) is executed this 1st day of February, 2022 (the “Effective
Date”), by and between BIOLIFE4D, a Delaware limited liability company formerly known as BIOGEN3D Corporation (the “Company”)
and Jeffrey Morgan (“Advisor”).

 

WHEREAS,
the Company and Advisor are parties to that certain Advisory Board Agreement, dated August 23, 2017 (the “Agreement”)
(all capitalized terms used herein but not otherwise defined shall have the meaning ascribed to such terms in the Agreement); and

 

WHEREAS,
the Company and Advisor desire to amend certain provisions of the Agreement as set forth in this Amendment.

 

NOW,
THEREFORE, in consideration of the provisions and undertakings set forth herein, and for other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the Company and Advisor, intending to be legally bound, hereby agree as follows:

 

	1.	Amendment
                                            to Agreement. The Agreement is hereby amended as follows: Exhibit A to the Agreement
                                            is hereby deleted in its entirety and replaced with the Exhibit A attached hereto.

 

	2.	Acknowledgments.
                                            The Company and Advisor hereby acknowledge and agree as follows:

 

		a.	The
                                            Company has paid all compensation due to Advisor pursuant to the Agreement for any and all
                                            services provided by Advisor to the Company prior to February 1, 2022; and
		b.	as
                                            of February 1, 2022, Advisor owns (i) 2,500 shares of non-voting common stock of the Company,
                                            and (ii) options to purchase 170,000 shares of non-voting common stock of the Company.

 

	3.	Force
                                            and Effect of Agreement. Except as expressly modified hereby, the Agreement and all exhibits
                                            thereto are in all respects ratified and confirmed, and all of the terms, conditions and
                                            provisions thereof shall remain in full force and effect. This Amendment shall be effective
                                            upon execution and delivery by each of the parties as of the Effective Date. From and after
                                            the Effective Date, any reference to the Agreement, as the case may be, shall be deemed a
                                            reference to the Agreement as amended hereby.

 

	4.	Governing
                                            Law. This Amendment will be governed by Illinois law without regards to its conflict
                                            of laws provisions.

 

	5.	Counterparts.
                                            This Amendment may be executed in one or more counterparts, including facsimile or electronic
                                            counterparts, each of which shall be deemed to be an original copy of this Amendment, and
                                            all of which, when taken together, shall be deemed to constitute one and the same agreement.
                                            Counterparts may be delivered via facsimile, electronic mail (including PDF, .tiff or any
                                            electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com)
                                            or other transmission method and any counterpart so delivered shall be deemed to have been
                                            duly and validly delivered and be valid and effective for all purposes.

 

[Signature
page follows.]

 

    	 

     

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Amendment by affixing their signatures where indicated below.

 

	COMPANY:	 	ADVISOR:
	 	 	 
	BIOLIFE4D
  CORPORATION	 	 
	 	 	 	 
	By:	/s/
    Steven Morris	 	/s/
  Jeffrey Morgan
	Name:	Steven
    Morris	 	Jeffrey
  Morgan
	Its:	Chief
    Executive Officer	 	 

 

[Signature
Page to Amendment to Advisory Board Agreement]

 

    	 

     

    

 

Exhibit
A

 

“Services”:

 

Effective
as of February 1, 2022, “Services” shall include as follows:

 

		●	(1)
                                            Participate in any/all required meetings via phone or Zoom.
		●	(2)
                                            Be reasonably accessible to the Company to provide guidance on overall strategy, laboratory
                                            setup and development, research strategy, research development and implementation, and other
                                            varied issues on an as-needed basis.
		●	(3)
                                            Help identify, advise on and potentially recruit potential employees, consultants, directors,
                                            advisors and other services providers to the Company.
		●	(4)
                                            Act in the capacity of Chief Medical Officer including undertaking any reasonable request
                                            by the CEO to fulfill requirements of the Chief Medical Officer.
		●	(5)
                                            Undertake any fulfill requirements resulting from SEC, NASDAQ and/or other regulatory agencies.
		●	(6)
                                            Provide services beyond services detailed above including but not limited to: assist with
                                            the design of the GLP preclinical studies, creation of data reports, establishment of the
                                            clinical criteria for human implantation, selection of trial sites, standardization of clinical
                                            protocols for implantation technique, postoperative care, and other services which are typical
                                            of Chief Medical Officer.

 

“Compensation”:

 

As
compensation for the services (1) through (5) above rendered pursuant to this Agreement, beginning February 1, 2022 Company shall pay
Advisor $2,500 per month for each month that Advisor has performed “Services” as described above. For further clarification,
the initial $2,500 payment shall begin in March, 2022 for services rendered in February, 2022. When services detailed above in (6) are
formally requested by CEO and provided by Advisor, Advisor’s cash compensation shall increase from $2,500 per month to $5,000 per
month.

 

In
addition, the Consultant shall be granted 2,000 options per month for the Company’s common stock pursuant to the Company’s
Stock Option Plan and the Company’s Restricted Stock Plan which are place at the time of each grant. All options shall be granted
after each month worked, and for clarification the initial stock option grant shall be in March, 2022 for services rendered in February,
2022.Exhibit
10.11

 

ADVISORY
BOARD AGREEMENT

 

THIS
ADVISORY BOARD AGREEMENT (this “Agreement”) is entered into on August 28, 2017 (the “Effective
Date”) by and between BIOLIFE4D Corporation, a Delaware corporation (the “Company”), and Dr.
Raimond Winslow (“Advisor”).

 

RECITALS

 

WHEREAS,
the Company desires to obtain the services of Advisor to serve on the Company’s Board of Advisors (the “Advisory Board”),
and the Advisor desires to serve on the Advisory Board, upon the following terms and conditions.

 

NOW,
THEREFORE, in consideration of the foregoing recital, which is incorporated into and made a part
of the Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,
the parties agree as follows:

 

AGREEMENT

 

1.
Advisory Board Member. The Company hereby
retains Advisor as a member of the Advisory Board, and Advisor accepts such position.

 

2.
Term. The term of this Agreement (the
“Term”) shall be the period commencing on the Effective Date and
terminating upon the later of either (1) 2 years from the Effective Date, or (2) upon immediate written notice delivered by either
party to the other for any or no reason.

 

3.
Position, Duties, Responsibilities.

 

a. Duties.
Advisor shall perform those services (“Services”) as reasonably requested by the Company from time to time,
including but not limited to the Services described on Exhibit A attached hereto. Advisor shall make himself reasonably available
to answer questions, provide advice and provide Services to the Company upon reasonable request from the Company.

 

b. Independent
Contractor; No Conflict. It is understood and agreed, and it is the intention of the parties hereto, that Advisor is an independent
contractor, and not the employee, agent, joint venture, or partner of the Company for any purposes whatsoever. To the extent necessary,
Advisor shall be solely responsible for any and all taxes related to the receipt of any compensation under this Agreement. Advisor hereby
represents, warrants and covenants that Advisor has the right, power and authority to enter into this Agreement and that neither the
execution nor delivery of this Agreement, nor the performance of the Services by Advisor will conflict with or result in a breach of
the terms, conditions or provisions of, or constitute a default under, any contract, covenant or instrument under which Advisor is now
or hereinafter becomes obligated.

 

    	1

    	 

    

 

4.
Compensation, Benefits, Expenses.

 

 a. Compensation. As consideration for certain of the Services to be rendered by Advisor hereunder, the Company shall pay Advisor the Compensation as defined on Exhibit A attached hereto.

 

b. Reimbursement
of Expenses. The Company shall promptly reimburse Advisor for any reasonable costs and expenses incurred by Advisor in connection
with any Services specifically requested by the Company and actually performed by Advisor pursuant to the terms of this Agreement. Each
such expenditure or cost shall be reimbursed only if: (i) with respect to costs in excess of $100, individually, Advisor receives prior
approval from the Company’s CEO or CFO or other executive for such expenditure or cost, and (ii) with respect to costs in less
than $100, individually, provided Advisor furnishes to the Company adequate records and other documents reasonably acceptable to the
Company evidencing such expenditure or cost. Company shall reimburse Advisor for any reasonable expenses incurred by Advisor in connection
with his in-person attendance at a Company board meeting, such expenses to include transportation, airline flights, hotels, and meals.

 

5.
Proprietary Information; Work Product; Non-Disclosure.

 

a. Proprietary
Information Defined. The Company has and/or will conceive, develop and/or own, and continues to conceive and develop, certain property
and intellectual rights and information, including, but not limited to, its business plans and objectives, products and services, client,
customer and employee information, financial projections, marketing plans, marketing materials, logos, and designs, and technical data,
inventions, research, recipes, processes, know-how, marketing strategies, algorithms, formulae, franchises, databases, computer programs,
computer software and other trade secrets, information relating to patents issued, patents pending, patent applications, trademarks,
service marks, copyrights, inventions, know-how or trade secrets, or otherwise to research and development efforts, methodologies, testing,
engineering, manufacturing, sales, finances, or operations (such as but not limited to processes, formulae, methods, designs, schematics,
plans, techniques, devices, manufacturing and/or testing procedures, sales, personnel information or data), intangible assets and industrial
or proprietary property rights which may or may not be related directly or indirectly to the Company’s business and all documentation,
media or other tangible embodiment of or relating to any of the foregoing and all proprietary rights therein of the Company (all of which
are hereinafter referred to as the “Proprietary Information”). Although certain information may be generally
known in the relevant industry, the fact that the Company uses it may not be so known. In such instance, the knowledge that the Company
uses the information would comprise Proprietary Information. Furthermore, the fact that various fragments of information or data may
be generally known in the relevant industry does not mean that the manner in which the Company combines them, and the results obtained
thereby, are known. In such instance, that would also comprise Proprietary Information.

 

    	2

    	 

    

 

b. General
Restrictions on Use. Advisor agrees to hold all Proprietary Information in confidence and not to, directly or indirectly, disclose,
use, copy, publish, summarize, or remove from the Company’s premises any Proprietary Information (or remove from the premises any
other property of the Company), except (i) during the Term to the extent authorized and necessary to carry out Advisor’s responsibilities
under this Agreement, and (ii) after termination of this Agreement, only as specifically authorized in writing by the Company. Advisor
shall protect the Proprietary Information against unauthorized use or disclosure with at least the
same degree of care that Advisor uses to protect its own proprietary or confidential information of a similar nature, but in no event
less than a reasonable degree of care. Notwithstanding the foregoing, such restrictions shall not apply to: (x) information which Advisor
can show was rightfully in Advisor’s possession at the time of disclosure by the Company; (y) information which Advisor can show
was received from a third party who lawfully developed the information independently of the Company or obtained such information from
the Company under conditions which did not require that it be held in confidence; or (z) information which, at the time of disclosure,
is generally available to the public.

 

The
Company may use the name of Advisor or Advisor’s affiliated university or any affiliated entity without the prior written approval
of Advisor or any affiliated entity, as the case may be, only so long as any such usage is limited to reporting factual events or circumstances
only. Information not requiring prior written approval of Advisor or affiliated entity shall include but is not limited to using Advisor’s
name, picture, biography and any information or videos regarding Advisor which is public. Company may state that Advisor is a member
of Company’s Advisory Board and/or is providing strategic scientific and/or biomedical engineering advice and/or services and/or
direction to Company, and may use information pertaining to Advisor for purposes including but not limited to Company website, marketing,
advertising, and fundraising.

 

c.
Ownership of Work Product. All Company Work Product (as hereinafter defined) shall be considered work(s) made for hire by Advisor
for the sole benefit of the Company and shall belong exclusively to the Company and its designees. “Company Work Product”
shall mean any and all works, ideas, inventions, improvements, discoveries, designs, writings, works of authorship, processes, formulas,
intellectual property, patents and all other documentation (whether or not patentable or copyrightable or constituting trade secrets
and whether or not reduced to writing or practice), that are authored, conceived, developed, first reduced to practice or discovered
by Advisor (whether alone or with others) (i) in the performance of the Services, (ii) that derive from information or materials Advisor
received from Company, or (iii) that relate to or result from the actual or anticipated business, work, research or investigation of
Company. All Company Work Product shall be promptly and fully disclosed by Advisor to Company. Advisor hereby assigns all right, title
and interest in and to such Work Product (including all intellectual property embodied therein) to Company. At Company’ request
and expense, Advisor shall execute, acknowledge and deliver such assignments, declarations, certificates and other documents as Company
may consider necessary or appropriate to properly evidence Company’s right, title and interest in the Company Work Product, and
all intellectual property rights embodied therein, including, but not limited to, all copyrights and patent rights, and to obtain full
protection therefor. Advisor shall execute any and all applications for domestic and foreign patents, copyrights or other proprietary
rights and do such other acts (including, among other things, the execution and delivery of instruments of further assurance or confirmation)
requested by Company to assign the Company Work Product to Company and to permit Company to file, obtain and enforce any patents, copyrights
or other proprietary rights in the Company Work Product. Advisor’s obligation to execute, or cause to be executed, any such instrument
or paper, shall indefinitely survive the termination or expiration of Advisor’s service on the Advisory Board. All Company Work
Product and all information related thereto shall be considered Proprietary Information and shall be subject to all of the restrictions
set forth in this Agreement.

 

    	3

    	 

    

 

 d. Return of Proprietary Information. Upon termination of this Agreement, Advisor shall promptly deliver to the Company all drawings, blueprints, manuals, specification documents, documentation, source or object codes, tape discs and any other storage media, letters, notes, notebooks, reports, flowcharts, and all other materials in its possession or under its control relating to the Proprietary Information and/or Services, as well as all other property belonging to the Company which is then in Advisor’s possession or under its control.

 

e. Remedies.
Nothing in this Section 5 is intended to limit any remedy of the Company under applicable state or federal law.

 

6.
Notice of Competitive Services and Non-solicitation
of Employees. During the Term and for 6 months thereafter, Advisor shall provide the Company with prior written notice if Advisor
intends to provide any services, as an advisor, employee, consultant or otherwise, to any person, company or entity that competes directly
with the Company, such written notice to include the name of the competitor. Advisor agrees that during the term of this Agreement and
for a period of three years thereafter, Advisor will not, other than on behalf of or for the benefit of Company: (i) recruit or hire
any employee, independent contractor or advisor of Company, or otherwise attempt to solicit or induce any such employee, independent
contractor or advisor to leave the employment of, or terminate their relationship or provisions of services with, Company; or (ii) otherwise
interfere with Company’s business relationship with any client, vendor, independent contractor or other party with whom Company
engages in business.

 

7.
Miscellaneous.

 

a. Notices.
Any notice required or otherwise made pursuant to this Agreement shall be in writing, sent by registered or certified mail properly
addressed, or by email to the other party using the information set forth above or such other information as may be designated by written
notice to the other party. Notice shall be deemed effective (i) three business days following the date of sending such notice if by mail,
(ii) on the day following deposit with an overnight courier, if sent by overnight courier, (iii) upon receipt if by personal delivery,
or (iv) upon confirmation of receipt through facsimile electronic means if by email.

 

b. Entire
Agreement. This Agreement and any documents attached hereto as Exhibits constitute the entire agreement and understanding between
the parties with respect to the subject matter herein and therein, and supersede and replace any and all prior agreements and understandings,
whether oral or written with respect to such matters. The provisions of this Agreement may be waived, altered, amended or replaced in
whole or in part only upon the written consent of both parties to this Agreement.

 

c. Severability,
Enforcement. If, for any reason, any prov1s10n of this Agreement shall be determined to be invalid or inoperative, the validity and
effect of the other provisions herein shall not be affected thereby, provided that no such severability shall be effective if it causes
a material detriment to any party.

 

d. Governing
Law. The validity, interpretation, enforceability, and performance of this Agreement shall be governed by and construed in accordance
with the laws of the State of Illinois, and the state and federal courts located in Cook County, Illinois shall have exclusive jurisdiction
of all suits and proceedings arising out of or in connection with this Agreement. Each party hereby submits to the jurisdiction of said
courts in Cook County, Illinois for purposes of any such suit or proceeding, and waives any claim that any such forum is an inconvenient
forum.

 

    	4

    	 

    

 

e. Waiver
of Jury Trial. EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE
COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT SUCH PARTY MAY
HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT, OR THE TRANSACTIONS
CONTEMPLATED BY THIS AGREEMENT. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (A) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY
HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER,
(B) EACH SUCH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (C) EACH SUCH PARTY MAKES THIS WAIVER VOLUNTARILY
AND (D) EACH SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN
THIS SECTION.

 

f. Injunctive
Relief. The parties agree that in the event of any breach or threatened breach of any of the covenants in Section 5 or 6, the damage
or imminent damage to the value and the goodwill of the Company’s business will be irreparable and extremely difficult to estimate,
making any remedy at law or in damages inadequate. Accordingly, the parties agree that the Company shall be entitled to injunctive relief
against Advisor in the event of any breach or threatened breach of any such provisions by Advisor (without having to post bond), in addition
to any other relief (including damages) available to the Company under this Agreement or under applicable state or federal law.

 

g. Attorneys’
Fees. The prevailing party in any claim or litigation in connection with this Agreement shall be entitled to recover from the non-prevailing
party all costs and expenses, including, without limitation, the prevailing party’s reasonable attorneys’ and paralegals’
fees and costs in connection with any such claim or litigation.

 

h. Counterparts.
This Agreement may be executed in any number of counterparts, each of which shall be enforceable, and all of which together shall
constitute one agreement.

 

......
[Remainder of page intentionally left blank.]

 

    	5

    	 

    

 

IN
WITNESS WHEREOF, each party hereto has duly executed this Agreement as of the Effective Date.

 

	COMPANY:
    BIOLIFE4D CORPORATION	 	ADVISOR
	 	 	 	 	 
	Signature:	/s/
    Steven Morris	 	Signature:	/s/
    Raimond Winslow
	 	 	 	 	 
	Print
    Name:	Steven
    Morris	 	Print
    Name:	Raimond
    Winslow
	 	 	 	 	 
	Title:	CEO	 	 	 

 

    	 

    	 

    

 

EXHIBIT
A

 

“Services”:

 

	 	●	Participate
    in quarterly meetings.
	 	●
    	Be
    reasonably accessible to the Company to provide guidance on overall strategy, laboratory setup and development, research strategy,
    research development and implementation, and other varied issues on an as-needed basis.
	 	●
    	Help
    identify, advise on and potentially recruit potential employees, consultants, directors, advisors and other services providers to
    the Company.

 

“Compensation”:

 

Company
shall: (a) pay Advisor $2,500 upon execution of this Agreement and $2,500 per 90 days until
Company consummates fundraising in excess of $5,000,000 (a “Qualified Financing”); (b) after Company consummates a
Qualified Financing, pay Advisor an amount equal to $5,000 per calendar quarter thereafter, payable within 10 days after the
beginning of each such calendar quarter; (c) grant to Advisor 2,500 shares of common stock of Company (the “Grant”), which
Grant shall be made within 180 days of the Effective Date and (d) grant to Advisor 10,000 options to purchase common stock of
Company at an exercise price equal to the fair market value of such common units as of the date hereof, as reasonably determined by
Company (the “Option”). The Option shall be granted no later than 1 year following the execution of this
agreement pursuant to a separate agreement containing customary terms and conditions acceptable to Company, including, but not
limited to, the following vesting schedule: (i) 50% of the Option shall vest on the two year anniversary of the Effective Date (the “Initial
Vesting Date”); and (ii) the remaining 50% of the Option shall vest on the three year anniversary of the Effective
Date.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}]]